Table 5 Precision data for the assay of FAV and APX in their raw materials.

From: Conventional and synchronous spectrofluorometric determination of the recently administered drugs for treatment of COVID-19 favipiravir and apixaban

FAV

APX

Sample concentration (ng mL−1)

% Recoverya (Intraday precision)

% Recovery* (inter-day precision)

Sample concentration (μg mL−1)

% Recovery* (Intraday precision)

% Recovery* (inter-day precision)

4

99.52

99.14

0.4

100.03

98.28

98.37

97.91

100.65

99.85

101.82

99.91

100.65

101.45

X′ ± S.D

99.88 ± 1.76

98.98 ± 1.00

X′ ± S.D

100.45 ± 0.36

99.85 ± 1.60

% RSD

1.76

1.01

% RSD

0.36

1.60

% Error

1.02

0.59

% Error

0.21

0.92

6

98.39

98.00

0.6

98.93

98.23

98.11

97.88

99.03

98.50

98.51

98.26

99.57

99.03

X′ ± S.D

98.34 ± 0.21

98.05 ± 0.19

X′ ± S.D

99.18 ± 0.34

98.58 ± 0.41

% RSD

0.21

0.20

% RSD

0.35

0.41

% Error

0.12

0.11

% Error

0.20

0.24

8

100.12

99.73

0.8

99.93

100.61

99.93

99.93

99.66

100.7

99.54

100.88

101.01

101.15

X′ ± S.D

99.86 ± 0.30

100.18 ± 0.61

X′ ± S.D

100.20 ± 0.71

100.82 ± 0.29

% RSD

0.30

0.61

% RSD

0.71

0.29

% Error

0.17

0.35

% Error

0.41

0.17

  1. *Each result is the average of three individual measurements.